Related Experiment Video
Updated: Jun 28, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Targeting WDR12 Unleashes T-Cell-Mediated Antitumor Activity in Melanoma by Destabilizing CD276
Jie Pan1,2,3,4,5,6, Ruimin Chang4,7, Meng Zhang7
1The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Melanoma is the deadliest skin cancer, and despite the success of immune checkpoint blockade, a substantial fraction of patients fail to respond. Tumors can evade cytotoxic lymphocytes by upregulating multiple inhibitory checkpoints. Here we identify WDR12 as a determinant of immunotherapy resistance: WDR12 expression is elevated in nonresponders, and its genetic inhibition increases intratumoral CD8+ T-cell infiltration and enhances cytotoxic function. Mechanistically, WDR12, in cooperation with the chaperonin subunit CCT7, stabilizes the immune checkpoint CD276 (B7-H3) on tumor cells, thereby suppressing T-cell activity and promoting immune escape. To translate these findings, we identify SU14813 as a small-molecule WDR12 inhibitor that binds WDR12 with high specificity, reduces CD276 stability, and relieves CD276-mediated T-cell suppression. In vivo, WDR12 targeting sensitizes tumors to PD-1 blockade, and combined SU14813 and anti-PD-1 therapy produces superior antitumor efficacy. These results define a WDR12-CCT7-CD276 axis that sustains immune resistance in melanoma and nominate WDR12 inhibition with PD-1 blockade as a promising therapeutic strategy.
Insights
WDR12 protein promotes melanoma immune evasion by stabilizing the CD276 checkpoint. Inhibiting WDR12 enhances T-cell activity and sensitizes tumors to PD-1 blockade, offering a new immunotherapy strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Melanoma is a deadly skin cancer with limited treatment responses.
- Tumors evade immune attack via inhibitory checkpoints, leading to immunotherapy resistance.
Purpose of the Study:
- Identify novel targets for overcoming melanoma immune resistance.
- Investigate the role of WDR12 in immunotherapy failure.
Main Methods:
- Assessed WDR12 expression in melanoma nonresponders.
- Utilized genetic inhibition of WDR12 to evaluate T-cell infiltration and function.
- Determined the mechanism involving WDR12, CCT7, and CD276 (B7-H3) stabilization.
- Identified and tested SU14813, a WDR12 inhibitor, in preclinical models.
Main Results:
- Elevated WDR12 expression correlates with immunotherapy nonresponse.
- WDR12 inhibition boosts intratumoral CD8+ T-cell infiltration and cytotoxic function.
- WDR12 stabilizes CD276, suppressing T-cell activity and promoting immune escape.
- SU14813 reduces CD276 stability and T-cell suppression.
- Combined SU14813 and anti-PD-1 therapy shows superior antitumor efficacy in vivo.
Conclusions:
- A WDR12-CCT7-CD276 axis drives melanoma immune resistance.
- Targeting WDR12 with PD-1 blockade is a promising therapeutic strategy for melanoma.
More Related Videos
10:04Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...